June 2015, Vol 8, No 4

This editorial is focused on the work of the Pharmacoeconomics and Cost Clinical Effectiveness (PEACE) committee, an important group that I have written about previously.
Oncology continues to be a major focus for all healthcare stakeholders, attracting intense investments in drug development for new therapies and diagnostics that keep fueling innovation while increasing concerns for the ever-rising cost of cancer care.
The American Cancer Society estimated that approximately 1 in 7 men will be diagnosed with prostate cancer during his lifetime.
Comparing Cost and Utilization of 2 Therapies for Metastatic Castration-Resistant Prostate Cancer
Multiple myeloma is a malignant B-cell neoplasm of terminally differentiated plasma cells that accumulate in the bone marrow and frequently invade the adjacent bone, leading to bone destruction and marrow failure.
The Rationale for Comparing the Costs of Competing Treatment Options in Oncology
Cancer is already the largest clinical area of drug spending in the United States, and a cluster of innovative medicines utilizing new mechanisms of action for patients with a wide variety of tumor types promise to further increase cancer-related spending.
“Innovation drives progress,” suggests the US Food and Drug Administration (FDA) in its report on the 41 new molecular entities and new biologic pharmaceuticals that were approved in 2014.

Results 1 - 6 of 6
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME